Complete financial analysis of Muromachi Chemicals Inc. (4885.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Muromachi Chemicals Inc., a leading company in the Chemicals industry within the Basic Materials sector.
- Strategic Education, Inc. (STRA) Income Statement Analysis – Financial Results
- Trejhara Solutions Limited (TREJHARA.BO) Income Statement Analysis – Financial Results
- ON Semiconductor Corporation (ON) Income Statement Analysis – Financial Results
- Johnson Chemical Pharmaceutical Works Co., Ltd. (4747.TWO) Income Statement Analysis – Financial Results
- TeraForce Technology Corporation (TERA) Income Statement Analysis – Financial Results
Muromachi Chemicals Inc. (4885.T)
About Muromachi Chemicals Inc.
Muromachi Chemicals Inc. plans, produces, and distributes pharmaceuticals and health foods in Japan. It offers active pharmaceutical ingredients and intermediate synthesis products; commissioned processing services for pharmaceuticals; and commissioned synthesis services for radioactive and stable isotope tagged compounds used in pharmaceutical and agricultural metabolic testing, as well as imports and sells active pharmaceutical ingredients. The company also provides jelly and non-alcoholic beverage products. In addition, it offers ion-exchange resins, separation membranes, and ion-exchange fibers; and solutions that meet customers' needs with water-treatment products, including filter media, equipment, and chemicals, as well as commissioned chemical processing services. Further, the company provides functional adhesives; and product contamination removal and dust removal mats, and antistatic products for use in the electronics industry, as well as engages in the commissioned manufacturing and processing of functional pastes. The company was founded in 1917 and is headquartered in Omuta, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 6.37B | 6.29B | 5.68B | 4.94B | 5.28B |
| Cost of Revenue | 4.55B | 4.54B | 3.95B | 3.29B | 3.70B |
| Gross Profit | 1.82B | 1.75B | 1.73B | 1.65B | 1.59B |
| Gross Profit Ratio | 28.53% | 27.85% | 30.50% | 33.41% | 30.04% |
| Research & Development | 29.27M | 33.07M | 29.03M | 32.02M | 25.62M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 114.00M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 1.12B |
| SG&A | 1.37B | 1.32B | 1.24B | 1.22B | 1.23B |
| Other Expenses | 0.00 | 10.14M | 5.41M | 3.11M | 3.88M |
| Operating Expenses | 1.40B | 1.38B | 1.30B | 1.28B | 1.29B |
| Cost & Expenses | 5.95B | 5.92B | 5.24B | 4.57B | 4.98B |
| Interest Income | 2.13M | 38.00K | 4.00K | 2.00K | 18.00K |
| Interest Expense | 18.46M | 17.69M | 17.01M | 27.68M | 30.67M |
| Depreciation & Amortization | 136.19M | 122.26M | 101.23M | 124.32M | 218.30M |
| EBITDA | 623.23M | 493.14M | 540.12M | 491.22M | 262.25M |
| EBITDA Ratio | 9.79% | 7.80% | 9.51% | 9.94% | 9.98% |
| Operating Income | 421.84M | 369.41M | 437.34M | 369.34M | 301.12M |
| Operating Income Ratio | 6.62% | 5.87% | 7.70% | 7.47% | 5.70% |
| Total Other Income/Expenses | 46.75M | -18.51M | -11.74M | -169.72M | -287.66M |
| Income Before Tax | 468.59M | 350.90M | 425.60M | 199.62M | 13.46M |
| Income Before Tax Ratio | 7.36% | 5.58% | 7.49% | 4.04% | 0.25% |
| Income Tax Expense | 138.39M | 94.60M | -30.67M | 18.90M | -20.93M |
| Net Income | 330.20M | 256.30M | 456.27M | 180.71M | 34.39M |
| Net Income Ratio | 5.18% | 4.07% | 8.03% | 3.66% | 0.65% |
| EPS | 83.42 | 67.94 | 123.79 | 65.24 | 17.16 |
| EPS Diluted | 81.86 | 64.12 | 112.56 | 56.97 | 17.16 |
| Weighted Avg Shares Out | 3.96M | 3.77M | 3.69M | 2.77M | 2.00M |
| Weighted Avg Shares Out (Dil) | 4.03M | 4.00M | 4.05M | 3.17M | 2.00M |
Source: https://incomestatements.info
Category: Stock Reports